
Phase 3 Study Shows Statistically Significant Survival With Tebentafusp in Metastatic Uveal Melanoma
Overall survival was statistically significantly improved with tebentafusp compared with investigator’s choice of therapy as treatment of patients with metastatic uveal melanoma in the phase 3 IMCgp100-202 study.









